CD9, a member of the tetraspanin family of proteins, is characterized by four transmembrane domains and two extracellular loops. Surface expression of CD9 on Chinese hamster ovary (CHO) cells dramatically enhances spreading and motility on fibronectin. To elucidate the mechanistic basis of CD9-fibronectin interaction, binding to fibronectin was investigated using purified and recombinant forms of CD9. The affinity of fibronectin for CD9 in enzyme-linked immunosorbent assay was 81 ؎ 25 nM. The binding of fibronectin to immobilized CD9 was enhanced by Ca 2؉ ions. Protein binding and peptide competition studies demonstrated that peptide 6 derived from CD9 extracellular loop 2 (amino acids 168 -192) contained part of the fibronectinbinding domain. Additionally, enhanced adhesion of CD9-CHO-B2 cells to fibronectin was significantly reduced by peptide 6. CD9-CHO cells had a 5-fold increase in motility to fibronectin as compared with mock-transfected controls, an effect that correlated with CD9 cell surface density. Truncation of CD9 extracellular loop 2 and peptide 6 caused inhibition of CD9-CHO cell motility to fibronectin. Deletion of CD9 extracellular loop 1 had no significant effect on CHO cell motility. These findings demonstrate a critical role for CD9 extracellular loop 2 in cell motility to fibronectin and clarify the mechanism by which CD9-fibronectin interaction modulates cell adhesion and motility.
The transmembrane 4 superfamily (TM4SF) 1 member, CD9, is a 24-kDa integral membrane glycoprotein expressed on numerous cell types, including platelets, endothelial cells, smooth muscle cells, cultured fibroblasts, pre-B cells, activated T cells, and glial cells (1) . Based on cDNA sequence analysis, the TM4SF members are predicted to be single polypeptide chains with four highly hydrophobic putative transmembrane (TM) regions and two extracellular (EC) loops with both the NH 2 and COOH termini localized intracellularly. The putative transmembrane domains and certain residues in the EC loops are highly conserved, suggesting that these proteins perform closely related functions (1) . The cellular function of the TM4SF proteins is not yet clear, but indirect data suggest that most TM4SF members mediate cellular functions such as adhesion, motility, and differentiation (1) .
The role of CD9 in many cell types has been investigated via anti-CD9 mAb perturbation studies. Anti-CD9 mAbs have been shown to mediate the proliferation, adhesion, and motility of neural cells (2) (3) (4) . An anti-CD9 mAb enhanced the migration of Schwann cells on living neurites and sciatic nerve sections (2) . Antibody-mediated enhancement of Schwann cell migration correlated with increases in cytosolic calcium and phosphoproteins. Ectopic expression of CD9 on nonmotile Raji cells gave rise to ␤ 1 integrin-dependent motility on FN (5) . CD9 was also found to participate in endothelial cell migration during wound repair (6) . Recent studies have shown that CD9 deficiency in mice does not significantly affect smooth muscle cell migration or neointima formation after vascular injury (7) . However, in the absence of CD9, one or more of the other TM4SF members may compensate for lack of CD9 function. Conversely, studies using CD9-null mice have demonstrated an essential role for CD9 in egg/sperm fusion (8, 9) . Previous studies have shown that high affinity binding between fertilin beta (ADAM2) and ␣ 6 ␤ 1 integrin requires cooperation between ␣ 6 ␤ 1 and CD9 (10) .
Immunoprecipitation studies on a number of cell types have shown that CD9 and other TM4SF members associate with integrins (1). CD9 was specifically coimmunoprecipitated from S-16 Schwann cell extracts using mAbs against integrins ␣ 4 , ␣ 6 , and ␤ 1 and double-immunofluorescence labeling studies suggested that CD9 colocalizes with these integrins on the cell membrane (11) . Recent studies have shown that prototype complexes of CD9, CD81, and ␣ 3 ␤ 1 and complexes of CD63 and phosphoinositide 3Ј-OH kinase may localize within lipid raftlike domains on the cell surface (12) . These data suggest that CD9 either interacts directly with ECM proteins or influences the activity of adhesion molecules indirectly via physical association or the modulation of intracellular signaling pathways.
We have previously demonstrated that surface expression of CD9 in CHO cells induced unique growth patterns and a dramatic enhancement of CHO cell spreading on the extracellular matrix protein, FN (13) . In this study, we showed that binding of purified FN to platelet-derived or recombinant CD9 was dose-dependent, enhanced by Ca 2ϩ ions, and that the affinity of this interaction was 80 nM. Part of the FN-binding domain was located within CD9 EC2 (residues 168 -192). A peptide spanning this EC2 region competitively inhibited the interaction of the CD9 with FN in a purified ELISA system and inhibited the adhesion of CD9-CHO-B2 cells to FN. We also showed that CHO cells with high CD9 surface density had significantly greater FN-directed cell motility as compared with mock-CHO cells. These effects were seen with two independent CHO cell clones and with two heterogenous populations of CD9-expressing CHO cells. Using CD9-CHO cells expressing a lower surface density of human CD9, we were able to demonstrate that CD9 surface density had a direct relationship with CHO cell motility to FN. Mutant CD9-CHO cells lacking regions of CD9 EC2 had significantly decreased haptotactic motility to FN. Additionally, CD9-mediated CHO cell motility was specifically blocked by peptide 6 corresponding to the FN binding site of CD9 EC2. Deletion of CD9 EC1 did not significantly affect CD9-mediated motility. These findings suggest that CD9-FN interaction markedly influences FN-directed CHO cell movement and that direct interaction between CD9 and FN is required for this effect.
EXPERIMENTAL PROCEDURES

Materials-
The wild type CHO cell line (CHO-K1 ATCC #CCl-61) was purchased from the American Type Culture Collection, Rockville, MD. The CHO-B2 cell line, deficient in ␣ 5 ␤ 1 expression, was kindly provided by Dr. R. Juliano of the University of North Carolina, Chapel Hill, NC (14) . Peptide 5 (YKDTYNKLKTKDEPQRETLKAI), peptide 6 (PKKDVLETFTVKSCPDAIKEVFDNK), and peptide 6S (KEFDFKA-PSVCKVEDIDTKTLPKVN) were either prepared and purified by Dr. Jerome Seyer and Dr. Bob Cassell, Veteran's Medical Center, Memphis, TN, or synthesized by Sigma Genosys (The Woodlands, TX). Cell culture medium RPMI 1640, trypsin, Geneticin, and human plasma FN were from Invitrogen, Gaithersburg, MD. Fetal bovine serum was from HyClone, Logan, UT. Immunochemical reagents included MIgG, p-nitrophenyl phosphate (Sigma, St. Louis, MO) polyclonal rabbit anti-FN (Invitrogen), and alkaline phosphatase-labeled goat anti-rabbit IgG (Southern Biotechnology, Birmingham, AL).
The antibodies RAP2 and mAb7 have been described previously (15, 16) . Plasmid pRc/CMVCD9 containing intact human CD9 cDNA was generated earlier (17) . The pQE30 expression vector and nickel-nitrilotriacetic acid-agarose were from Qiagen, Valencia, CA. Mammalian expression vector pRc/CMV was from Invitrogen. Cloning vector pBluescript II SKϩ was from Stratagene (La Jolla, CA). LipofectAMINE transfection reagent, Opti-MEM I reduced serum medium, molecular biology reagents (including restriction endonucleases), modifying enzymes, T4 DNA ligase, and Taq DNA polymerase were all purchased from Invitrogen. PCR oligonucleotide primers were synthesized by Sigma Genosys. All other chemicals were from Sigma Chemical Co., St. Louis, MO.
Media and buffers-Media A was 90% (v/v) RPMI, 10% (v/v) fetal calf serum. Media B consisted of RPMI containing 1% (w/v) BSA. Media C was 85% (v/v) RPMI, 15% (v/v) fetal calf serum. Standard ELISA buffers comprised of buffer A (50 mM HEPES, 3.5 mM CaCl 2 , 0.5 mM EGTA, pH 7.0), blocking buffer 1 (buffer A plus 5% BSA plus 0.05% Tween 20), buffer B (buffer A plus 1% BSA plus 0.05% , and buffer C (buffer B minus CaCl 2 ). ELISA buffers for metal cation studies were as follows; buffer D (50 mM HEPES, 0.5 mM EGTA, pH 7.0), buffer E (buffer D plus 1% BSA plus 0.05% Tween 20), Blocking buffer 2 (buffer D plus 5% BSA plus 0.05% Tween 20 plus 0 -4.5 mM metal salt), buffer F (buffer A plus 1% BSA plus 0.05% Tween 20 plus 0 -4.5 mM metal salt), and buffer G (buffer F minus metal salt). 1 mg/ml p-nitrophenyl phosphate in 10% (v/v) diethanolamine, 5 mM MgCl 2 , pH 9.8, was used for the ELISA substrate.
ELISA for FN Binding-All incubation periods for the CD9-FNbinding ELISA lasted 2 h at room temperature unless indicated. Immulon I (VWR International, Bristol, CT) microtiter plate wells were coated with CD9 (2 g/ml), His 6 -rCD9 (2 g/ml), BSA (10 g/ml), or peptide (10 M) in buffer A. After one wash with buffer B, plates were blocked with blocking buffer 1. 1% BSA was included in steps from ligand overlay to addition of mAb conjugate to minimize nonspecific binding. Titrations of human plasma FN in buffer B were added to plates either alone or, in the case of competition ELISAs, with 0 -160 M synthetic peptide. Plates were washed three times with ELISA buffer B, followed by incubation with a 1/1000 dilution of rabbit anti-FN antibody. After two washes with buffer B and one wash with buffer C, plates were incubated with 1/500 anti-rabbit IgG alkaline phosphatase in buffer C for 1 h at room temperature. After four washes with buffer C, 1 mg/ml p-nitrophenyl phosphate substrate was added and the absorbance at 405 nm was recorded.
The standard ELISA assay format was modified to evaluate the effects of divalent and monovalent metal salts on the FN-CD9 interaction. The ELISA buffers contained 0.5 mM EGTA, and metal salt was excluded from antigen plating and the primary wash step. Antigen was plated in buffer D. The plates were washed once with buffer E and then blocked with blocking buffer 2. Subsequent steps up to and including the second wash after the FN overlay were done in buffer F, which contained 0 -4.5 mM metal salt. After the FN overlay, plates were washed once with buffer F (with or without metal salt), then twice with buffer G. The subsequent incubations and washes were performed with buffer G.
Recombinant CD9 Synthesis-CD9 cDNA (bp 153-839) was PCRamplified from the lF-5 clone (17) , and the PCR product (rCD9) was sequenced using the dideoxy-chain termination method. The purified rCD9 cDNA was ligated into the pQE30 expression vector (Qiagen) and transfected into Escherichia coli (SG13009). His 6 -rCD9 was expressed, and recombinant CD9 protein was purified with nickel-nitrilotriacetic acid-agarose according to the manufacturer's protocol.
CD9 Deletion Mutations-The isolation and cloning of CD9 cDNA into the mammalian expression vector pRc/CMV (pRc/CMVCD9) has been described previously (17) . A CHO cell clone transfected with pRc/ CMVCD9 was designated CD9-CHO-N3 (17) . A second CD9 CHO cell clone, CD9-CHO-A6, was generated for this study using the pRc/ CMVCD9 plasmid as described previously (17) . The strategy for the deletion of the CD9 EC2 and TM4 regions (⌬113-228) has been described elsewhere (13) .
The oligonucleotide primers used to construct the CD9 EC2 truncation cDNAs were designed according to the reported CD9 nucleotide sequence (17) . These oligonucleotide primers were used in PCR amplifications using full-length CD9 cDNA as a template to generate mutant CD9 cDNAs. Three PCR amplifications were used to construct CD9 EC2 deletions. The first PCR was done using full-length CD9 cDNA as a template with a CD9 SphI 5Ј primer (5Ј-CAGTGCATGCTGGGACTGT-TCTTCGGCTTC-3Ј) containing the SphI site at position ϩ416 in the CD9 open reading frame with either 3Ј ⌬133-192 (5Ј-TGCGCCGATG-ATGTGGAACAGCTTGTTGTAGGT-3Ј), 3Ј ⌬152-192 (5Ј-GCCGATGA-TGTGGAAGTTCAACGCATAGTG-3Ј) or 3Ј ⌬173-192 (5Ј-GCCGATGA-TGTGGAATACGTCCTTCTTGGG-3Ј) primers generating 154-, 208-, and 271-bp fragments, respectively.
The second PCR was done using full-length CD9 cDNA as a template with a 3Ј ApaI primer (homologous to the pRc/CMV vector backbone sequence) with either 5Ј ⌬133-192 (5Ј-ACCTACAACAAGCTGTTCCA-CATCATCGGCGCA-3Ј), 5Ј ⌬152-192 (5Ј-CACTATGCGTTGAACTTC-CACATCATCGGC-3Ј), or 5Ј ⌬173-192 (5Ј-CCCAAGAAGGACGTATTC-CACATCATCGGC-3Ј) primers, respectively, generating a 611-bp fragment in each case.
For the third PCR amplification, corresponding overlapping PCR products were utilized as templates and extended for 15 cycles, after which CD9 SphI and ApaI primers were used for an additional 30 cycles to generate CD9 EC2 internal deletion products of 765 bp for ⌬133-192, 819 bp for ⌬152-192, and 882 bp for ⌬173-192. These PCR products were cleaved with SphI and ApaI and subcloned into the pBSSKCD9 vector backbone from which the SphI/ApaI portion of the CD9 cDNA/vector sequence had been removed generating complete CD9 cDNAs with the targeted regions in CD9 EC2 missing. The CD9 EC2 truncation cDNAs were subcloned into the original pRc/ CMVCD9 construct from which the full-length CD9 cDNA had been removed. The fmole DNA sequencing system (Promega, Madison, WI) was used to obtain and confirm CD9 EC2 truncation cDNA sequences. In summary, ⌬133-192, ⌬152-192, and ⌬173-192 CD9 cDNAs had truncations of 180 bp (60 aa), 123 bp (41 aa), and 60 bp (20 aa) in CD9 EC2, respectively.
To construct ⌬23 CD9 cDNA with an internal deletion of 72 nucleotides (24 aa) spanning CD9 EC1, a 686-bp BamHI/PstI fragment of CD9 encoding CD9 cDNA was amplified using pRc/CMVCD9 as a template using DAWfor (5Ј-GGATCCATGCCGGTCAAAGG-3Ј) and DAWrev (5Ј-CTGCAGCTAGACCATCTCGC-3Ј) primers. This fragment was digested with BamHI and PstI and cloned into complementary sites in the vector pGEM-T (Promega, Madison, WI) yielding the pGDAW construct. To delete CD9 EC1, pGDAW was amplified using DAWfor and ⌬23rev (5Ј-GACTCCTGTCCATAGTCCAAT-3Ј) primers. The ⌬23rev primer contained a T 323 -C 254 nucleotide junction in the CD9 sequence. 5 l of the first PCR product was mixed with 1 ng of pGDAW plasmid and subjected to one PCR cycle of 5 min at 95°C, 2 min at 37°C, and 10 min at 70°C. The product of the second PCR was then amplified for 30 cycles using DAWfor and DAWrev primers generating the 617-bp BamHI/PstI CD9 EC1 deletion fragment. The CD9 EC1 deletion product was digested with BamHI and PstI and cloned into the complementary sites of the plasmid pGEM-T thus generating pGAW/D35. The pGAW/D35 plasmid was grown and purified from E. coli. A 617-bp BamHI/PstI fragment from pGAW/D35 was isolated and subcloned into the BamHI/PstI site of pcDNA3.1Zeo to generate pcDNA/⌬23. The REP4CD9 expression vector was made by amplification of CD9 cDNA by PCR using pRc/CMVCD9 as a template and primers CD9for (5Ј-GATCAAGCTTATGCCGGTCAAAGG-3Ј) and CD9rev (5Ј-GATCG-GATCCCTAGACCATCTCGC-3Ј) containing HindIII and BamHI restriction sites, respectively. The resulting DNA amplified by PCR was digested with HindIII and BamHI and cloned homologous sites of the pREP4 vector.
Cell Transfections-Wild type CHO cells were grown to 50 -70% confluency in six-well tissue culture plates (Corning Glass, Corning, NY) containing 3 ϫ 10 5 cells/well. Cells were rinsed once with serumfree RPMI 1640 and transfected with 2 g of plasmid DNA using LipofectAMINE according to the manufacturer's protocol. At 72 h posttransfection, cells were passed 1:10 in selective growth media supplemented with 750 g/ml Geneticin G418 or 1 mg/ml Zeocin, and stable transfectants were selected. Two mock control transfections were done, "Mock" for pRc/CMV and "Mock-Zeo" for PcDNA3.1Zeo. The heterogenous populations of CD9-expressing CHO cells CD9-CHO-H1, CD9-CHO-H2, and REP4-CD9-CHO were made by electroporation with either pRc/CMVCD9 or pREP4CD9 for REP4-CD9-CHO cells. Briefly, washed CHO cells were resuspended at 5 ϫ 10 7 in PBS, mixed with 20 g of the appropriate plasmid DNA, and pulsed at 500 V, 900 microfarads, and 125 ohms using a ECM 630 electro-cell manipulator (BTX, San Diego, CA). Stable CD9-expressing CHO cells were selected by growth in the presence of either 750 g/ml Geneticin for pRc/CMVCD9 or 400 g/ml hygromycin for pREP4CD9-transfected CHO cells.
Cell Culture-Cell cycle-synchronized cultures were used for all assays. CD9-or Mock-CHO cells were enriched at the G O /G 1 stage by the seeding of confluent cells at 2 ϫ 10 6 cells/75-cm 2 flask and harvesting at 50 -70% confluency. All Mock-transfected or CD9-transfected CHO K1 cells were maintained in media A supplemented with either 750 g/ml Geneticin (Invitrogen) or 1 mg/ml Zeocin (Invitrogen) depending on expression vector selection marker. The heterogenous CHO cell line transfected with pREP4CD9 was grown in media A supplemented with 400 g/ml hygromycin.
Motility Assays-The motility assays were performed using two methodologies. The first method was modified from Bauer et al. (18) . Cell cycle-synchronized CHO cells were seeded into tissue culture plates, grown to ϳ50% confluency, and harvested. The cells were washed twice with media A, adjusted to 4 ϫ 10 5 /ml, allowed to rest at 37°C for 30 min in media B, then transferred into modified Boyden chambers. The upper and lower chambers were separated by a polycarbonate filter with 8-m pores, pre-coated on the underside only with 10 g/ml FN. After 3 or 6 h, cells on the FN-coated side of the filters were fixed, stained with hematoxylin, and mounted onto slides. The total numbers of adherent cells from five high powered fields (HPF) per filter were counted per time point per assay.
The second method for assessing the motility of CD9-transfected CHO cells utilized 10-mm polycarbonate tissue culture inserts with 8-m pores (Nunc, Rochester, NY). Tissue culture inserts were coated on the underside with FN as described above for Boyden chambers. For peptide inhibition studies FN-coated tissue culture inserts were coated with either peptide 6 or scrambled peptide control (referred to as 6S) at 0.5 M in PBS for 2 h at 37°C and allowed to dry at 4°C overnight. 300 l of media B was added to each well of a 24-well culture plate (Nunc, Rochester, NY), and a coated tissue culture insert was placed in each well. CHO cells were cell synchronized, harvested, and prepared as described for Boyden chamber motility experiments. 400 l (3 ϫ 10 5 cells/ml) of CHO cell suspension was added per coated tissue culture insert. CHO cells were allowed to migrate for 3 or 6 h at 37°C. CHO cells, adhered to the FN-coated underside of tissue culture inserts, were stained with Wright Giemsa, and the number of adherent cells in five random high power fields were counted per time point per assay. Comparison studies confirmed that there were no significant differences in the extent of CHO cell motility between the two methods described (data not shown).
Adhesion Assays-CHO cell adhesion assays were done as described by Cook et al. (13) . Briefly, 24-well cell culture plates (Corning, Acton, MA) were coated with FN (10 g/ml) and blocked with PBS, 3% BSA. CHO cells were cell synchronized, harvested, and resuspended at 1 ϫ 10 5 cell/ml in adhesion media (RPMI, 1% BSA). For peptide inhibition studies, peptides were added to CHO cell suspension to give a final concentration of 0.5 M, and cells were incubated at 37°C for 30 min. 1-ml CHO cell suspension was added to each well, and CHO cells were allowed to adhere for either 3 or 6 h when adherent cells were stained with Wright Giemsa and counted.
RESULTS
CD9
Binding to Fibronectin Is Calcium-dependent-As previous studies had suggested a role for CD9 in cell adhesion and spreading on FN (13), we assayed purified CD9 for FN binding activity. The interaction between CD9 and FN was stimulated by CaCl 2 (Fig. 1A) . Although other cations, including Na ϩ and K ϩ , had no effect on CD9-FN interaction, Mg 2ϩ showed some enhancement of CD9-FN binding (data not shown). Half-maximal binding was seen at ϳ1 mM interactions in the presence of 2.5 mM CaCl 2 are shown in Fig.  1B . In the absence of Ca 2ϩ ions, the binding is lower, and saturation is not reached at 200 g/ml FN (data not shown). The binding of FN to purified platelet CD9 was compared with bacterially expressed histidine tagged CD9 (His 6 -rCD9) and BSA (Fig. 1B) . The absolute values from ELISA showed that the binding of His 6 -rCD9 to FN was 40% lower than for purified CD9; however, half-maximal binding between His 6 -rCD9 and FN was 120 nM FN, close to the value obtained for purified CD9 (81 Ϯ 25 nM).
To address the specificity of the CD9-FN interaction, peptides corresponding to different regions of CD9 EC2 were assayed for FN binding activity ( Fig. 2A) . Peptide 5 (YKDT-YNKLKTKDEPQRETLKAI) and Peptide 6 (PKKDVLETFT-VKSCPDAIKEVFDNK) correspond to CD9 EC2 amino acids 125-146 and 168 -192, respectively. When compared with intact platelet-purified CD9, soluble FN had significant binding to peptide 6 (65%) compared with 19% for peptide 5. Competition ELISAs were used to examine the effects of the CD9 peptides on the binding of FN to CD9 (Fig. 2B) . Peptide 6 significantly inhibited the binding of FN to CD9 where maximal inhibition was seen at 60 M peptide (Fig. 2C) . To demonstrate that CD9 was able to bind to FN in a whole cell system, CHO-B2 cells lacking integrin ␣ 5 ␤ 1 expression were transfected with CD9, and their ability to adhere to FN was compared with CHO-B2 Mock transfectants. CD9 expression induced a significant increase in CHO-B2 adhesion to FN (Fig.  2D) . In support of our observations in a purified ELISA system, peptide 6, unlike scrambled control peptide 6S, was able to block the enhanced CD9-CHO-B2 cell adhesion to FN demon- CHO cell motility to FN was assessed as described under "Experimental Procedures." After 3 h the total number of adherent cells per five high power fields (HPF) per filter were counted per time point per experiment. In each experiment, the greatest mean value for cells/HPF obtained for any screened condition was defined as 100%. The data from each run are expressed as the percentage of the maximum cell count. Mean values for each time point from the three experiments were averaged and are given as the mean Ϯ S.D. CD9 effects on CHO-K1 cell motility were tested using clone A6 and two heterogenous populations of CD9-expressing CHO cells demonstrating that CD9 affects on CHO cell motility were not influenced by clonal variation (p Ͼ 0.005). REP4CD9-CHO expressed significantly less CD9 than CHO cells transfected with pRc/CMVCD9. REP4CD9-CHO cells had a 42% reduction in motility to FN demonstrating a direct relationship between CD9 surface density and CHO cell motility to FN. strating that CD9 was responsible for this effect. These data demonstrate that CD9 can act as an FN receptor in a cellular context.
CD9 Expression Enhances CHO Cell Motility to Fibronectin-
The CD9-CHO-N3 clonal cell line was isolated from CHO cells transfected with pRc/CMVCD9 (17) . Polycarbonate filters coated with either fibrinogen or BSA had no adhered CD9-CHO-N3 cells in motility assays after 6 h (data not shown). The CD9-CHO-A6 clone described in this study was derived from CHO cells transfected with pRc/CMVCD9. Both CD9-CHO-N3 and CD9-CHO-A6 cell clones had high surface expression of CD9 as demonstrated by flow cytometry. For example, over 93% of CD9-CHO-A6 cells expressed CD9 with a mean fluorescence intensity (MFI) of 760 on labeling with mAb7 compared with Mock-CHO cells with an MFI of 6.7. To demonstrate that CD9 effects on CHO cell motility were not due to aberrant clones, two clonally heterogenous populations of CD9-expressing CHO cells were generated. Both CD9-CHO-H1 and CD9-CHO-H2 had equivalent CD9 cell surface density seen with clones CD9-CHO-A6 and CD9-CHO-N3 (data not shown). Additionally, a heterogenous CD9-expressing CHO cell population was produced using the pREP4CD9 expression vector. CD9-CHO-REP4 expressed CD9 with an MFI of 46, demonstrating that CD9-CHO-REP4 cells expressed significantly less CD9 than the clonal or heterogenous CD9-expressing CHO cells transfected with the pRc/CMVCD9 expression construct.
To assess the influence of CD9 on cell motility, we compared the haptotactic motility of Mock and CD9-CHO cells to FN in modified Boyden chambers. CD9-CHO cells had a 5-fold increase in their motility when compared with Mock-CHO cells (Fig. 3) . CD9-CHO-H1 and CD9-CHO H2 had the same enhancement of CHO cell motility to FN as seen with CD9-CHO-A6 (Fig. 3) , demonstrating that aberrant CHO cell clones were not responsible for the changes in CHO cell motility. Additionally, CD9-CHO-REP4 had a 45% reduction in haptotactic motility to FN as compared with the other CD9-expressing CHO cell lines (Fig. 3) . These data point to a direct relationship between CD9 cell surface density and the enhancement of CHO cell motility to FN. Overall, we conclude that CD9 expression on CHO cells is associated with increased haptotactic motility to FN. Mock-, CD9-, or CD9 EC2 deletion mutants to FN was measured using the Boyden chambers as described under "Experimental Procedures." Removal of CD9 EC2, TM4, and COOH-terminal resulted in a 58% reduction in motility. Cells expressing CD9 internal deletions of aa residues 133-192 and 152-192 demonstrated a 60 and 64% reduction in motility, respectively, over 6 h (p Ͻ 0.05). In addition, cells transfected with a CD9 truncation containing a part of the FN binding site (CD9 ⌬173-192) exhibited a reduction of motility of 45%. B, the motility of CHO-K1 cells expressing CD9 EC1 deletion mutant (⌬23) was compared with the Mock transfection (Mock-Zeo) and CHO-CD9-A6 expressing full-length CD9. Deletion of CD9 EC1 has no significant effect on CD9-mediated CHO cell motility on FN at 6 h (p Ͼ 0.005). C, peptide 6 corresponding to the putative FN binding site on CD9 EC2 (aa 168 -192) competitively inhibited CD9-mediated CHO cell motility to FN (p Ͻ 0.005). The specificity of this effect was shown by a lack of inhibition with a scrambled Peptide 6 (Peptide 6S).
CHO Cells Expressing CD9 Truncations Had Decreased Haptotactic Motility to FN-In
168 -192 in CD9 EC2 competitively inhibited binding of FN to purified CD9 in a dose-dependent fashion (Fig. 2C) . Therefore, we hypothesized that this region on CD9 EC2 could be important in mediating FN-directed motility of CD9-CHO cells.
To test whether the FN binding site is required for CD9-mediated cell motility, we constructed several CD9 deletion mutants. Four CD9 truncations were located in CD9 EC2. CD9 ⌬113-228 contained a 114-aa deletion encompassing the whole EC2 loop, the fourth TM domain, and the third cytoplasmic domain. ⌬133-192 contained an internal deletion of 60 aa, and ty-four clones were selected and expanded for further characterization. The CHO cell clones expressing mutant CD9 had equivalent surface density compared with WT CD9 when used as an internal control (19) . Northern blot analysis also confirmed a comparable expression of mutant CD9 RNA when compared with the CD9-expressing CD9 N3 clone (19) . Earlier studies have shown that the CD9 EC2 truncation ⌬113-228, lacking CD9 EC2, TM4, and the COOH-terminal, can be detected on the surface of CHO cells at equivalent density to full-length CD9 using the CD9 EC1-specific polyclonal antibody RAP2 (13) . CHO cell clones containing CD9 truncations were analyzed for haptotactic motility to FN. CHO cells expressing CD9 truncations within the FN binding site of CD9 EC2 exhibited reduced FN-mediated haptotactic motility (Fig.  4A) . Cells expressing CD9⌬152-192 demonstrated a 60% reduction in motility over 6 h compared with CHO cells expressing full-length CD9 (p Ͻ 0.05). CD9⌬133-192 exhibited a 64% reduction in motility (p Ͻ 0.05). CD9⌬113-228-CHO (deletion of CD9 EC2, TM4, and COOH-terminal) showed a 58% reduction in motility to FN. Differences in the values for percent reduction of motility for cells expressing CD9 EC2 deletions ⌬113-228, ⌬133-192, and ⌬152-192 were not statistically significant. Cells transfected with a CD9 truncation where part of the FN binding site was expressed (CD9⌬173-192-CHO) exhibited a reduction in motility of 45%. Motility of CHO cells expressing CD9 EC1 deletion (⌬23) was compared with its mock transfection (Mock-Zeo), CD9-CHO-N3 (complete wild type CD9 sequence). Deletion of CD9 EC1 had no significant effect on CHO cell motility to FN (p Ͼ 0.05) (Fig. 4B) .
To further characterize the region of CD9 EC2 responsible for CD9-modulated CHO cell haptotaxis, motility was assessed under conditions where FN-coated tissue culture inserts had been blocked with peptide 6 corresponding to CD9 EC2 aa 168 -192. As shown in Fig. 4C , 45% inhibition of CD9-directed CHO cell motility to FN was observed in the presence of peptide 6. The specificity of this effect was demonstrated by use of a scrambled version of peptide 6 (peptide 6S). In summary, these results point to the importance of the FN-binding region on CD9 EC2 for cellular haptotactic motility and suggest that CD9 EC2 aa 168 -192 contains a functional domain associated with FN-directed motility. The structures of CD9 truncations are shown in Fig. 5 .
DISCUSSION
The TM4SF member CD9 has been implicated in several cellular functions, including motility, proliferation, and spreading. The mechanism of CD9 effects on these functions is not clear, but CD9 may act via direct interaction with ECM proteins or indirectly via the modulation of integrin-mediated signaling pathways. The direct interaction between CD9 and several ECM proteins was investigated. CD9 was found to specifically bind to FN in a Ca 2ϩ -dependent manner. FN has recognition sequences that mediate cell attachment, cell spreading, and migration as well as pericellular FN matrix assembly. Thus, CD9 may elicit some of its effects by modulating cell-FN interactions as a result of CD9 protein binding directly to FN. Studies using CD9-transfected CHO-B2 cells demonstrated that CD9 is able to mediate CHO cell adhesion to FN in the absence of the classic FN receptor, integrin ␣ 5 ␤ 1 . The identification of FN as a direct target of CD9 binding provides the first readily measured receptor function for CD9.
The validity and specificity of the CD9-FN interaction were demonstrated by complementary approaches: 1) FN was shown to bind to either purified platelet CD9 or a recombinant form of CD9, and 2) the FN binding site on CD9 was partially defined using synthetic CD9 peptides, one of which competitively inhibited CD9-FN interaction. The ELISA studies provided strong support for a specific interaction between CD9 and FN. To eliminate the possibility that the FN binding assessed by these methods may be due to contamination of an integrin in the purified CD9 preparation, we generated a bacterially expressed recombinant form of CD9 and demonstrated that both platelet-derived and bacterially generated CD9 had a similar affinity for FN binding. In support of these data, a specific association between FN captured by anti-FN mAbs and purified CD9 was detected by surface plasmon resonance biosensor analysis. 2 This demonstration of CD9-FN interaction confirmed that CD9 was also able to bind to FN in its native conformation. FN bound directly to Peptide 6, which corresponds to CD9 residues 168 -192, a portion of CD9 EC2. Peptide 6 partially inhibited the CD9-FN interaction in competition studies. These data suggest that CD9 residues 168 -192 contain part, but not all, of the FN-binding sequences on CD9 EC2.
CD9-and Mock-CHO cells were generated to study the effects of CD9 expression on cell adhesive function. The CD9-CHO-A6 cells had increased spread morphology on FN in adhesion assays (13) . Here, we demonstrate that CD9 expression significantly enhances FN-directed CHO-cell haptotactic motility, and residues 168 -192 of CD9 EC2 are associated with increased FN-directed cell motility. Based on these findings we postulate that extracellular ligand interaction is required for CD9-mediated cell haptotactic motility.
The data described in this study clearly demonstrate that CD9 expression induces increased CHO cell motility. These findings are at variance with earlier studies showing that CD9 expression on CHO cells resulted in a reduction in CHO cell motility (20, 21) . There are several possible reasons for these conflicting data. CHO-K1 was the parental cell line for our studies, in contrast to previous reports where mutant CHO cell lines that had specific nutritional requirements were used to generate CD9-expressing CHO cell lines (20, 21) . Additionally, our study specifically focused on CD9 effects on CHO cell motility to FN. Earlier studies examined the effects on CD9 expression on the ability of CHO cells to penetrate Matrigel-coated filters. The Matrigel preparation described in these studies consisted of primarily laminin, collagen IV, and heparan sulfate proteoglycan and did not contain significant quantities of FN (22, 23) . The cell invasion assays described in these studies were run for of 16 -24 h as compared with the 3-6 h where statistically significant enhancement of CHO cell motility to FN was observed on CD9 expression. Previous reports have utilized phagokinetic track assays to study CD9 effects on CHO cell motility that provide readouts of random motility. In contrast, our studies specifically address CD9-haptotactic motility to a specific ligand, FN.
How CD9 influences cellular phenotype is not yet clear. The data presented here suggest that CD9 influences cell adhesive functions by binding directly to FN. Numerous studies have demonstrated that CD9 can form complexes with other adhesive molecules such as integrins (1) . CD9 has been detected in a number of integrin complexes that include ␣ 5 ␤ 1 , ␣ 4 ␤ 1 , ␣ 3 ␤ 1 , and ␣ 6 ␤ 1 (1, 24 -26) . In addition, CD9, CD81, and ␤ 1 and ␣ 3 integrin subunits were detected in the cell membrane footprints and rippings of motile keratinocytes suggesting a role for tetraspanin-integrin complexes in adhesion to ECM and keratinocyte motility (27) . It has also been proposed that CD9 modulates integrin-mediated signaling pathways. A recent study (28) has shown that a subset of TM4SF members, including CD9, can act as linker proteins for the recruitment of protein kinase C to integrins. The specificity for protein kinase C association was thought to depend upon the cytoplasmic tails or the first two TM regions of the TM4SF members. A specific association between ␣ 3 ␤ 1 , the TM4SF member CD151, and phosphatidylinositol 4-kinase was detected in neutrophils, and antibodies to either ␣ 3 ␤ 1 or CD151 were able to reduce neutrophil motility (29) . It is conceivable that CD9 and ␣ 5 ␤ 1 work in concert, because the downregulation of both has been associated with decreased metastatic potential (30) . In support of this idea, CD9 was detected in complex with ␣ 5 ␤ 1 in CD9-transfected CHO cell lysates.
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TM4SF EC2 domains appear to be critical for their associations with other proteins. For example, amino acids 186 -217 of CD151 EC2 and aa 570 -705 of the ␣ 3 subunit were required for CD151/␣ 3 ␤ 1 integrin association (24) . The association of CD9 with the recently identified cell surface protein CD9P-1 was dependent on CD9 EC2 (31) . It is feasible that deletions of CD9 EC2 may affect its association with CHO cell ␣ 5 ␤ 1 leading to a reduction in motility to FN. However, CD9 association with ␣ 5 ␤ 1 has only been observed in nonstringent CHAPS detergent cell lysates (26) suggesting that CD9/␣ 5 ␤ 1 association could be indirect. A recent study has shown that CD9 is involved in the invasion of a human choriocarcinoma cell line (32) , and CD9 was detected in complex with ␣ 5 integrins on the surface of this cell line (27) .
In summary, CD9 represents a new class of FN receptor. CD9 shows no structural homology to the integrin family of FN receptors (33) . However, recent evidence suggests that CD9 may function by binding to FN and by associating with various members of the integrin family or other surface molecules (1, 24 -26, 30) . Because transmembrane regions of CD9 and the other tetraspanin proteins are highly conserved, it seems likely that the transmembrane regions are important in mediating common signaling events, whereas their unique EC regions confer different cell type-or stage-dependent functions. The coordination of CD9 direct ligand binding activity and its association with other surface molecules may be in part responsible for mediating cell-specific functions. In support of this idea, a recent study of canine kidney cells showed that CD9 coexists in distinct multimolecular complexes that were relative to the subcellular location. In the same study anti-TM4SF or activatory anti-␤ 1 mAbs were able to induce the formation of tube-like structures in CHO cells (34) . Additionally, CD9 has been demonstrated to have a profound effect on FN matrix assembly, a process regulated by high affinity states of integrin ␣ 5 ␤ 1 (13) . How CD9 influences integrin activity and cellular phenotype remains to be investigated.
